At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 24, 2026 at 16:01 ET
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing three Class II directors, ratifying Deloitte & Touche LLP as auditors, approving an amendment to exculpate officers from certain fiduciary duties, and adjourning the meeting if needed. This is a routine annual shareholder meeting with no material financial impact.
- Election of three Class II directors: Andrew Guggenhime, David Johnson, and Nancy Whiting
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026
- Approval of amendment to provide for exculpation of officers from certain breaches of fiduciary duty
- Approval of adjourning the 2026 Annual Meeting if necessary for further solicitation of proxies
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access